ERBB2 and breast cancer: Neoadjuvant treatment with four cycles of single-agent nab-paclitaxel 150 mg/m2 qw 3/4 was safe and effective in the phase II GEICAM trial in patients with early-stage, hormone receptor-positive, HER2-negative BC [38, 39].